Interruption of Perinatal Transmission of Hepatitis B Virus (HBV) With a Recombiant Yeast-derived Hepatitis B Vaccine and Immunogenicity—9 Years of Follow-up

Objective To assess the long-term efficacy of recombinant yeast-derived hepatitis B vaccine in infants born to HBsAg and HBeAg carrier mother. Methods A total of 273 neonates born to HBsAg,HBeAg both positive mothers were vaccinated with 5,5,5 μg doses of recombinant yeast-derived hepatitis B vaccine by 0,1, and 6 months schedule.They were all followed for 1-9 years after the primary vaccination. Results Twelve infants (6.63%) become HBsAg positively conversed in 9 year after primary vaccination,and the positive Rate of HBsAg in 1-9 year was 0.72%-6.8%,17.8% of child in no/lowly-respond become HBsAg positively.At the ninth year the positive rates of anti-HBs were 60% above.Anti-HBs positive rates and immunity level were higher at 3-5 year old by repetition immunity than others. Conclusion The recombinant yeast-derived hepatitis B vaccine have good immunogenecity and long-term protective efficacy to HBV interruption of perinatal transmission,a booster dose seems necessary in aged 3-4 years to the mother with HBsAg and HBeAg.It is high-risk to become HBsAg positively in the baby of norespones to hepatitis B vaccine.